This week on Pharm5:

• OTC Narcan (naloxone)


• Higher dose Rybelsus (semaglutide)


• iPLEDGE REMS in discussion


• WHO COVID-19 guidance for healthy kids


• Pradaxa (dabigatran) recall

Connect with us!

• Listen to our podcast: Pharm5


• Follow us on Twitter: @LizHearnPharmD

References:

1. FDA approves first over-the-counter naloxone nasal spray. U.S. Food and Drug Administration. http://bit.ly/42O0I8a. Accessed March 29, 2023.


2. Hoffman J. Over-the-counter Narcan could save more lives. but price and stigma are obstacles. The New York Times. http://bit.ly/3lWSrhF. Published March 28, 2023. Accessed March 30, 2023.


3. Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial. Novo Nordisk. http://bit.ly/3nBDJNG. Published March 24, 2023. Accessed March 30, 2023.


4. Ozempic® (semaglutide) injection-A1C control within your control for a range of T2D patient Needs1,2,4,5. novoMEDLINK. http://bit.ly/40ISVHv. Accessed March 30, 2023.


5. FDA panel votes to modify isotretinoin iPLEDGE REMS. Medscape. http://bit.ly/3FZIU0c. Published March 29, 2023. Accessed March 30, 2023.


6. The iPLEDGE REMS Prescriber Guide. iPLEDGE REMS. http://bit.ly/3lU85ue. Published October 2021. Accessed March 30, 2023.


7. Hassan C, Regan H. Who experts revise covid-19 vaccine advice, say Healthy Kids and teens low risk. CNN. http://bit.ly/3KlyOJt. Published March 29, 2023. Accessed March 30, 2023.


8. Mueller B, Hoffman J. Routine childhood vaccinations in the U.S. slipped during the pandemic. The New York Times. http://bit.ly/3ziptMc. Published April 21, 2022. Accessed March 30, 2023.


9. Birth-18 years immunization schedule – healthcare providers. Centers for Disease Control and Prevention. http://bit.ly/3JXI3y7. Published February 10, 2023. Accessed March 30, 2023.


10. Ascend Laboratories LLC. issues voluntary nationwide recall of dabigatran etexilate capsules, USP 75 mg and 150 mg, due to the detection of N-Nitroso-Dabigatran (NDAB) impurity. U.S. Food and Drug Administration. http://bit.ly/3TUrGXN. Accessed March 30, 2023.